

To: [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] @rivm.nl]; [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] @rivm.nl]; [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] @rivm.nl]; [redacted] 5.1.2e
Cc: [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] @astrazeneca.com]
From: [redacted] 5.1.2e [redacted] 5.1.2e
Sent: Tue 3/30/2021 4:12:53 PM
Subject: FYI - RWE studie uit Wales en eerste monthly safety report
Received: Tue 3/30/2021 4:13:37 PM
[Hollinhurst et al. preprint RWE Wales.pdf](#)
[01 Public Safety Update VAXZEVRIA 29 March 2021 \(1\).pdf](#)

Beste allen,

Hierbij stuur ik jullie ter informatie een nieuwe preprint van een RWE studie uit Wales, waarin bewoners van verzorgingstehuizen 1 vaccinatie met AZD1222 of met BNT162b2 hebben gekregen. Deze pre-print (not peer-reviewed) is vorige week verschenen.

Key points:

- Observational data-linkage study (SAIL Databank) of vaccinated elderly care home residents in Wales, UK (n=14,104; mean age 85 yrs) to evaluate the risk of SARS-CoV-2 infection 7- or 21-days post-vaccination with first dose of AZD1222 (89.1%) or BNT162b2 (10.9%)
 - 148 infections were recorded; 90% ≤28 days and 99% ≤42 days post-first dose
- At 7 days, risk of SARS-CoV-2 infection was significantly reduced for individuals with prior infection (multivariable analysis; HR 0.54 [95% CI, 0.30–0.95])
- At 21 days, frailty was associated with greater risk of SARS-CoV-2 infection (HR 4.59 [1.23–17.12] and 4.85 [1.68–14.04] for individuals with low and intermediate frailty scores, respectively)
- At 7 days, risk of infection was higher for those receiving BNT162b2 than AZD1222 (HR 3.83 [2.45–5.98])
- At 21 days, no significant difference between AZD1222 and BNT162b2
- Authors concluded there is a susceptible period of infection up to 42 days post-first dose of vaccine and therefore extra precautions to reduce transmission should be taken

Daarnaast stuur ik hierbij ter info de public assessment of van het eerste monthly safety report van het AstraZeneca vaccin, die de EMA op hun website gaat plaatsen (zie bijlage). Het is belangrijk om te weten dat hierin nog **niet** de beoordeling van de trombose/trombocytopenie is opgenomen.

In het document komen jullie een andere naam voor het AstraZeneca vaccin tegen komen (Vaxzevria). We zullen as donderdag tijdens ons overleg hier meer achtergrondinformatie over geven. De SmPC met de nieuwe naam is te downloaden via:

[redacted]
5.1.2h

Bij eventuele vragen, hoor ik het graag.

Groeten, [redacted] 5.1.2e

[redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e
[redacted] 5.1.2e

AstraZeneca BV

Prinses Beatrixlaan 582, 2595 BM Den Haag

T [redacted] 5.1.2e M: +31 [redacted] 5.1.2e
[redacted] 5.1.2e @astrazeneca.com

Please consider the environment before printing this e-mail

This e-mail is intended solely for the use of the addressee and is not meant for distribution or disclosure outside AstraZeneca. The information in this e-mail may be personal or confidential. Any views or opinions presented do not necessarily represent those of AstraZeneca. Should you receive this message by mistake, please notify the sender immediately and delete this e-mail from your system without opening the attachment.